|Articles|October 14, 2019
Characterization and Formulation Screening of mAb and Antibody-Drug Conjugates (ADCs) by High-throughput DLS
Author(s)Wyatt
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
AI, CRISPR, and mRNA Driving Biotech’s Smartest Decade Yet
2
Top 10 BioPharm International Articles of 2025
3
FAQ: Understanding Biosimilars, Biobetters, and Interchangeability
4
Integrated Platform Eliminates Ex-Vivo Expansion Barrier for CAR-T Access
5